OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 6.76 EUR 5.3% Market Closed
Market Cap: 151.1m EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one OSE stock under the Base Case scenario is 4.84 EUR. Compared to the current market price of 6.76 EUR, OSE Immunotherapeutics SA is Overvalued by 28%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OSE Relative Value
Base Case
4.84 EUR
Overvaluation 28%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.8
P/S
P/S
Price to Sales
1.8
vs History
90
vs Industry
80
Median 3Y
4.1
Median 5Y
6.1
Industry
6.9
Forward
3.1
More Details
3.9
P/E
P/E
Price to Earnings
3.9
vs History
6
vs Industry
12
Median 3Y
-3.8
Median 5Y
-7.1
Industry
22.4
Forward
15.9
More Details
3
P/OCF
P/OCF
Price to OCF
3
vs History
11
vs Industry
16
Median 3Y
-4.1
Median 5Y
-6.3
Industry
19.1
More Details
3.3
P/FCFE
P/FCFE
Price to FCFE
3.3
vs History
28
vs Industry
13
Median 3Y
2.9
Median 5Y
-4.5
Industry
23.2
More Details
2.3
P/B
P/B
Price to Book Value
2.3
vs History
66
vs Industry
47
Median 3Y
2.7
Median 5Y
2.7
Industry
2.5
More Details
2
EV/S
EV/S
Enterprise Value to Sales
2
vs History
84
vs Industry
74
Median 3Y
4.8
Median 5Y
6.2
Industry
7.5
Forward
3.6
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.9
More Details
3.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
3.4
vs History
3
vs Industry
16
Median 3Y
-5.7
Median 5Y
-7.7
Industry
4
Forward
10.1
More Details
3.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
3.9
vs History
3
vs Industry
14
Median 3Y
-4.6
Median 5Y
-6.9
Industry
3.7
Forward
10
More Details
3.5
EV/OCF
EV/OCF
Enterprise Value to OCF
3.5
vs History
6
vs Industry
18
Median 3Y
-4.9
Median 5Y
-6.8
Industry
4.5
More Details
3.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
3.5
vs History
6
vs Industry
14
Median 3Y
-4.9
Median 5Y
-6.7
Industry
3.4
More Details
1.7
EV/IC
EV/IC
Enterprise Value to IC
1.7
vs History
73
vs Industry
48
Median 3Y
2
Median 5Y
2.1
Industry
4.6
More Details

Multiples Across Competitors

OSE Competitors Multiples
OSE Immunotherapeutics SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
OSE Immunotherapeutics SA
PAR:OSE
147.6m EUR 1.8 3.9 3.4 3.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 047 871.8 -166 577.3 -202 278 -199 969.8
US
Abbvie Inc
NYSE:ABBV
344.9B USD 6.1 81.3 16.1 24.2
US
Amgen Inc
NASDAQ:AMGN
149.4B USD 4.5 36.6 15.1 26.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.2B USD 11.7 -241.2 26.4 27.7
US
Gilead Sciences Inc
NASDAQ:GILD
128.2B USD 4.5 266.6 10.5 13.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 010.1 -512.9 -558.5 -543.6
AU
CSL Ltd
ASX:CSL
124.3B AUD 5.3 29.2 17.9 22.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
66.5B USD 4.7 15 9.5 10.6
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.4 -63.9 -57.7
NL
argenx SE
XBRU:ARGX
35.1B EUR 18.2 47.7 -2 697.2 -1 808.3
P/S Multiple
Revenue Growth P/S to Growth
FR
OSE Immunotherapeutics SA
PAR:OSE
Average P/S: 3 186 359.8
1.8
-27%
N/A
FR
Pharnext SCA
OTC:PNEXF
35 047 871.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
7%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
E
Epizyme Inc
F:EPE
2 010.1
N/A N/A
AU
CSL Ltd
ASX:CSL
5.3
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.7
6%
0.8
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
18.2
39%
0.5
P/E Multiple
Earnings Growth PEG
FR
OSE Immunotherapeutics SA
PAR:OSE
Average P/E: 68.6
3.9
-52%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -166 577.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.3
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
36.6
44%
0.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.2 N/A N/A
US
Gilead Sciences Inc
NASDAQ:GILD
266.6
187%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -512.9 N/A N/A
AU
CSL Ltd
ASX:CSL
29.2
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15
10%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.4 N/A N/A
NL
argenx SE
XBRU:ARGX
47.7
28%
1.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
OSE Immunotherapeutics SA
PAR:OSE
Average EV/EBITDA: 14.1
3.4
-62%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 278 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
15.1
17%
0.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.4
18%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
10.5
7%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.5 N/A N/A
AU
CSL Ltd
ASX:CSL
17.9
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.5
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 697.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
OSE Immunotherapeutics SA
PAR:OSE
Average EV/EBIT: 18.4
3.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 969.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.2
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.7
31%
0.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.7
17%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
13.2
11%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -543.6 N/A N/A
AU
CSL Ltd
ASX:CSL
22.4
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.6
13%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 808.3 N/A N/A

See Also

Summary
OSE intrinsic value, competitors valuation, and company profile.
DCF Valuation
OSE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
OSE stock valuation using valuation multiples.
Wall Street Estimates
OSE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
OSE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 252,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.